

Randomised double-blind cross-over trial of proglumide in patients with chronic pain and/or fatigue

Submission date 30/09/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 30/09/2004	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 03/11/2015	Condition category Respiratory	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Derek R Haines

Contact details

Anaesthetic Department
Hull and East Yorkshire Hospitals NHS Trust
Hull Royal Infirmary
Anlaby Road
Hull
United Kingdom
HU3 2JZ

Additional identifiers

Protocol serial number

N0084096586

Study information

Scientific Title

Randomised double-blind cross-over trial of proglumide in patients with chronic pain and/or fatigue

Study objectives

Does proglumide offer benefit to fearful chronic pain patients, and/or patients with the chronic fatigue syndrome?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised double-blind cross-over trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Signs and Symptoms: Pain

Interventions

Randomised double blind cross-over design. Baseline week of symptom diaries and questionnaires. Four weeks on either proglumide or inactive preparation, then mid study questionnaires. Four weeks on crossover preparation. Final questions.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Proglumide

Primary outcome(s)

Primary end-point: less fearfulness (as measured by anxiety and activity avoidance) in the proglumide phase of the crossover trial.

Key secondary outcome(s)

Secondary end-points: reduced pain scores during the proglumide phase, increased fearfulness during the ascorbic acid phase in placebo responders.

Completion date

01/09/2002

Eligibility

Key inclusion criteria

40

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Does not match inclusion criteria

Date of first enrolment

01/02/2000

Date of final enrolment

01/09/2002

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Hull Royal Infirmary

Hull

United Kingdom

HU3 2JZ

Sponsor information

Organisation

Department of Health

Funder(s)

Funder type
Other

Funder Name
The North and South Bank Research and Development Consortium (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes